Local delivery of parathyroid hormone-related protein-derived peptides coated onto a hydroxyapatite-based implant enhances bone regeneration in old and diabetic rats by Ardura, Juan A. et al.
For Peer Review
 
 
 
 
 
 
LOCAL DELIVERY OF PARATHYROID HORMONE-RELATED 
PROTEIN-DERIVED PEPTIDES COATED ONTO A 
HYDROXYAPATITE-BASED IMPLANT ENHANCES BONE 
REGENERATION IN OLD DIABETIC RATS 
 
 
Journal: Journal of Biomedical Materials Research: Part A 
Manuscript ID Draft 
Wiley - Manuscript type: Original Article 
Date Submitted by the Author: n/a 
Complete List of Authors: Ardura, Juan A; Instituto de Investigacion Sanitaria de la Fundacion 
Jimenez Diaz, Laboratorio de Metabolismo Mineral y Óseo 
Portal-Núñez, Sergio; Insituto de Investigación Sanitaria-Fundación 
Jiménez Díaz, Laboratorio de Metabolismo Mineral y Óseo, Laboratorio de 
Metabolismo Mineral y Oseo 
Gutierrez-Rojas, Irene; Instituto de Salud Carlos III, Centro de 
Investigaciones Biomédicas en Red de Diabetes y Enfermedades 
Metabólicas Asociadas (CIBERDEM) 
Lozano, Daniel; Insituto de Investigación Sanitaria-Fundación Jiménez 
Díaz, Laboratorio de Metabolismo Mineral y Óseo 
Sanchez-Salcedo, Sandra; Universidad Complutense, Madrid, Spain. Centro 
de Investigación Biomédica en Red de Bioingeniería, Biomateriales y 
Nanomedicina (CIBER-BBN), Departamento de Química Inorgánica y 
Bioinorgánica, Facultad de Farmacia,  
Lopez-Herradon, Ana; Instituto de Investigación Sanitaria (IIS)-Fundación 
Jiménez Díaz and UAM Madrid, Laboratorio de Metabolismo Mineral y Oseo 
Mulero, Francisca; Centro Nacional de Investigaciones Oncológicas (CNIO), 
Unidad de Imagen Molecular 
Villanueva-Peñacarrillo, Maria L; Instituto de Salud Carlos III, Centro de 
Investigaciones Biomédicas en Red de Diabetes y Enfermedades 
Metabólicas Asociadas (CIBERDEM),  
Vallet-Regí, Maria; Universidad Complutense, Madrid, Spain. Centro de 
Investigación Biomédica en Red de Bioingeniería, Biomateriales y 
Nanomedicina (CIBER-BBN), Departamento de Química Inorgánica y 
Bioinorgánica, Facultad de Farmacia 
Esbrit, Pedro; Insituto de Investigación Sanitaria-Fundación Jiménez Díaz, 
Laboratorio de Metabolismo Mineral y Óseo, Laboratorio de Metabolismo 
Mineral y Oseo 
Keywords: 
N- and C-terminal PTHrP, gelatin–glutaraldehyde-coated hydroxyapatite, 
bone regeneration, aging, diabetes 
  
 
John Wiley & Sons, Inc.
Journal of Biomedical Materials Research: Part A
For Peer Review
 
Page 1 of 29
John Wiley & Sons, Inc.
Journal of Biomedical Materials Research: Part A
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 1 
LOCAL DELIVERY OF PARATHYROID HORMONE-RELATED PROTEIN-
DERIVED PEPTIDES COATED ONTO A HYDROXYAPATITE-BASED 
IMPLANT ENHANCES BONE REGENERATION IN OLD DIABETIC RATS 
Juan Antonio Ardura1,2*, Sergio Portal-Núñez1,2*, Irene Gutiérrez-Rojas3, Daniel 
Lozano1,2,4, Sandra Sánchez-Salcedo4, Ana López-Herradón1, Francisca Mulero5, 
María L. Villanueva-Peñacarrillo3, María Vallet-Regí4 and Pedro Esbrit1,2. 
 
1 Laboratorio de Metabolismo Mineral y Óseo, Instituto de Investigación Sanitaria (IIS)-Fundación Jiménez 
Díaz and UAM, Madrid, Spain  
2 RETICEF- Instituto de Salud Carlos III, Madrid, Spain 
3Centro de Investigaciones Biomédicas en Red de Diabetes y Enfermedades Metabólicas Asociadas 
(CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain. 
4Departamento de Química Inorgánica y Bioinorgánica, Facultad de Farmacia, Universidad Complutense, 
Madrid, Spain. Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y 
Nanomedicina (CIBER-BBN), Spain. 
5 Unidad de Imagen Molecular, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain  
* These authors have the same author status 
  
Corresponding author: 
 
Pedro Esbrit, Ph.D. 
Laboratorio de Metabolismo Mineral y Óseo 
Instituto de Investigación Sanitaria (IIS)-Fundación Jiménez Díaz  
Avda. Reyes Católicos, 2 
28040 Madrid (Spain) 
Phone: + 34 91 550 4894 
e-mail: pesbrit@fjd.es 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Page 2 of 29
John Wiley & Sons, Inc.
Journal of Biomedical Materials Research: Part A
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 2 
Abstract 
 
Diabetes mellitus (DM) and aging are associated with bone fragility and 
increased fracture risk. Both (1-37) N- and (107-111) C-terminal parathyroid 
hormone-related protein (PTHrP) exhibit osteogenic properties. We here aimed 
to evaluate and compare the efficacy of either PTHrP (1-37) or PTHrP (107-
111) loaded into gelatin–glutaraldehyde-coated hydroxyapatite (HA-Gel) foams 
to improve bone repair of a transcortical tibial defect in aging rats with or without 
DM, induced by streptozotocin injection at birth. Diabetic old rats showed bone 
structural deterioration compared to their age-matched controls. Histological 
and µ-computerized tomography studies showed incomplete bone repair at 4 
weeks after implantation of unloaded Ha-Gel foams in the transcortical tibial 
defects, mainly in old rats with DM. However, enhanced defect healing, as 
shown by an increase of bone volume/tissue volume and trabecular and cortical 
thickness and decreased trabecular separation, occurred in the presence of 
either PTHrP peptide in the implants in old rats with or without DM. This was 
accompanied by newly formed bone tissue around the osteointegrated HA-Gel 
implant and increased gene expression of osteocalcin and vascular endothelial 
growth factor (bone formation and angiogenic markers, respectively), and 
decreased expression of Sost gene, a negative regulator of bone formation, in 
the healing bone area. Our findings suggest that local delivery of PTHrP (1-37) 
or PTHrP (107-111) from a degradable implant is an attractive strategy to 
improve bone regeneration in aged and diabetic subjects. 
 
 
Keywords: N- and C-terminal PTHrP, gelatin–glutaraldehyde-coated 
hydroxyapatite, bone regenerarion, aging, diabetes. 
 
 
Page 3 of 29
John Wiley & Sons, Inc.
Journal of Biomedical Materials Research: Part A
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 3 
1. Introduction 
 
Osteoporosis, characterized by reduced bone strength and bone loss, is highly 
prevalent in aging westernized societies, and adversely affects the health of the 
elderly people by causing fragility fractures.1,2 Diabetes mellitus (DM), a 
metabolic disease with also increasing prevalence throughout the world, occurs 
frequently in the elderly, coexisting with osteoporosis.3 Chronic complications 
induced by DM adversely affect multiple organs, including bone, and cause an 
enormous medical and economic burden.4 In both type 1 and 2 DM, bone 
structure is altered, associated with an increased fracture risk, delayed fracture 
healing and potential fracture nonunion.5 Moreover, a growing body of research 
shows that type 2 DM increases the fracture risk independent of factors such as 
bone mineral density and age, currently used for predicting fractures.6 It has 
been hypothesized that DM-associated alterations in the skeleton might be 
added to those related to aging, further increasing bone fragility in diabetic old 
patients. In this scenario, the development of suitable approaches to improve 
fracture healing in these subjects is likely to have a great socioeconomic 
impact.  
Strategies to promote bone healing after fractures include providing cell 
precursors, growth factors, nutrients and/or synthetic materials to the injured 
area to induce tissue regeneration and replace bone tissue damage.7 Materials 
mimicking the bone mineral composition, including biodegradable gelatin–
glutaraldehyde-coated hydroxyapatite foams (HA-Gel) with attractive properties 
for application in bone such as osteointegration and osteoconduction, have 
been used in bone tissue engineering.8 Adsorption of a diversity of factors to 
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these materials to be used as implants has proved to improve their 
osteoinductive capacity.9  
Parathyroid hormone (PTH)-related protein (PTHrP) is now emerging as 
an attractive cytokine in this respect. PTHrP contains a N-terminal 1–37 region 
with high homology to PTH and a C-terminal region -containing the highly 
conserved 107–111 sequence, named osteostatin for its anti-bone resorption 
activity10-, displaying osteogenic features both in vitro and in vivo.11 Interestingly 
in this regard, systemic administration of N- or C-terminal PTHrP peptides has 
been reported to reverse at least in part the alterations in bone structure and/or 
osteoblast differentiation and function in a well characterized type 1 DM mouse 
model and in Igf1-null mice.12-14 Moreover, we previously showed that 
osteostatin coating onto various implant types of ceramics or even porous 
titaniums accelerates healing of critical and non-critical bone defects in the long 
bones of adult rabbits and rats.15,16  
These observations prompted us to evaluate and compare the efficacy of 
different PTHrP peptides to promote bone regeneration in a combined aging 
and DM scenario using a well characterized diabetic model. We used 
degradable HA-Gel foams as a template for PTHrP (1-37) or PTHrP (107-111) 
delivery in a cortical bone defect performed in aging rats with or without 
concomitant DM.  
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2. Materials and methods 
 
 
2.1. Preparation of HA-Gel foams 
Tridimensional macroporous HA-Gel foams have been synthesized in a 
one-step process, using the sol–gel technique for preparing nanocrystalline HA, 
including a non-ionic surfactant in the synthesis, Pluronic F127 
(EO106PO70EO106), as macropore former in the accelerated evaporation induced 
self assembly (EISA) method as described elsewhere.17 Briefly, HA was 
synthesized from the reaction of calcium nitrate tetrahydrate and 
triethylphosphite (TIP; Aldrich, Steinheim, Germany), using a molar ratio of 
F127:TIP of 11. The resulting foams were coated by immersion in a 1.2% (w/v) 
type A gelatin crosslinked with 0.05% w/v glutaraldehyde solution and then 
lyophilized for 24 h.13 The final foams (Supplementary Fig. 1) were 
characterized by Hg porosimetry in an AutoPore III porosimeter (Micromeritics 
Instrument Corporation, USA), scanning electron microscopy (SEM) in a JEOL 
6400 microscope (Tokyo, Japan) and X-ray diffraction (XRD) in a Philips X’Pert 
diffractometer using Cu Ka radiation. Characterization details of this material 
have been previously reported.17  
HA-Gel foams were loaded with either PTHrP (1-37) or PTHrP (107-111) 
(Bachem, Bubendorf, Switzerland) by soaking in a solution of each peptide (at 
100 nM) in phosphate-buffered saline, pH 7.4 (PBS) under stirring for 24 h in 
the cold room.13 Peptide uptake and release from these materials was 
determined by measuring absorbance at 280 nm of remaining peptide in the 
saline solution at different times. By using this method, the mean uptake of 
PTHrP (1-37) or PTHrP (107-111) by these foams after 24 h of loading was 
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about 60 percent for each peptide, equivalent to 5.0 or 0.7 ng peptide/mg 
material, respectively. Eighty percent of this amount of each PTHrP peptide was 
released to the surrounding medium within 1 h, and virtually 100 percent at 2 
and 5 days for PTHrP (107-111) and PTHrP (1-37), respectively. 
 
2.2 Animals  
Male Wistar rats were bred at our facility. Rats were placed in cages 
under standard conditions (room temperature 20 ± 0.5ºC, relative humidity 55 ± 
5% and illumination with a 12 h/12 h light/dark photoperiod), without restriction 
of movement, maintained on a standard pellet diet (UAR Panlab, Barcelona, 
Spain) and tap water ad libitum.  
On the day of birth, DM was induced by a single intraperitoneal injection of 
streptozotocin (100 µg/g of body weight) dissolved in 0.9% NaCl. It was 
previously shown that this model is characterized by a diabetic syndrome 
manifested by depletion of insulin stores and impaired glucose disposal in the 
adult.18 Rats showing a glucose disappearance constant (K) below 
2.5×10−2/min after an i.v. glucose tolerance test (50 mg glucose/Kg of body 
weight in 30 s) performed prior to sacrifice were selected as diabetic at an age 
range of 18-20 months. These animals displayed low plasma insulin, also 
consistent with previous studies18,19 (Fig. 1A-C). All aged rats –made diabetic or 
not- were of the same age (18–20 months old) and weight (Fig. 1D) by the time 
of the study as described below.  
A group of adult rats aged 6 months was used as younger controls of the 
old group of rats in order to confirm the age-related bone deterioration. Intact 
femora from the younger and aged rats were dehydrated and embedded in 
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methylmethacrylate, and 7-µm sections of the distal femur were stained with 
Goldner’s trichrome for light microscopy examination of the distal metaphysis.15 
Old diabetic rats showed less bone volume per total tissue volume ratio [bone 
volume (BV) over total volume (TV)] and lower trabecular thickness than the old 
control and the young group of rats, and decreased trabecular separation and 
trabecular number than the younger group (Table 1).  
Animal housing and care protocols were approved by the Animal Use 
Committee of the IIS-Fundación Jiménez Díaz, following the European Union 
guidelines to decrease pain and suffering of the animals. Our protocol using a 
limited number of rats (n = 5-10 per experimental group) complied with the 3R 
(“replace, reduce, and refine”) experimental design recommendation. 
 
 
2.3 Rat model of bone healing 
Experimental details of the procedure to generate a transcortical defect in 
the proximal rat tibia have been recently reported.12,15  In brief, aged rats with or 
without DM were anaesthetized with intramuscular injection of 25 mg/kg 
ketamine and 10 mg/Kg xylazine. A hole of 2 mm diameter was then drilled 
through the cortex, using continuous washing with saline, in both proximal tibial 
metaphysis. The left and right tibial defect received the unloaded and PTHrP-
loaded material, respectively, in each rat. Four weeks post-surgery, a period 
that has been proved insufficient for complete bone regeneration after the same 
surgical procedure in young rats,15 the animals were euthanized using an 
overdose of ketamine and xylazine, and the long bones were removed and kept 
frozen at -20ºC until processing. 
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2.4 Bone histology and µ-computerized tomography (µCT) analysis 
The tibial defects were scanned using GE eXplore Locus µCT scanner (GE 
Healthcare, London, Canada). Image acquisition was performed at 80 kV and 
450 µA, collecting 400 projections in one full rotation of the gantry. The resulting 
raw data were reconstructed using a filtered back-projection algorithm to a final 
image with a resolution of 93 µm in all three spatial dimensions. Cubic regions 
corresponding to cortical or trabecular peri-implant areas with a voxel size of 46 
µm in all length, width and height were cropped as the region of interest (ROI). 
The reconstructed images corresponding to these ROI were viewed and 
analyzed using MicroView software, version 2.2 with Advanced Bone Analysis 
plus (GE Healthcare). Bone structural parameters including cortical and 
trabecular bone volume/tissue volume (% BV/TV), thickness, bone surface/bone 
volume (% BS/BV) as well as trabecular number and separation were 
calculated in these areas.  
Rat tibiae hosting the different implants were fixed in 10% neutral 
formaldehyde for 24h followed by 70% ethanol and subsequently were 
decalcified with Osteosoft (Merck, Madrid Spain) for 4 eeks, dehydrated and 
embedded in paraffin using a Leica TP 1020 tissue processor. Histological 
assessment was performed on saggital 4-µm tissue sections around the implant 
in the tibial metaphysis by Masson’s trichromic staining. Bone collagen fibers 
stains blue (light blue: collagen fibers randomly arranged, characterizing early 
immature bone; dark blue: trabecular and cortical mature bone), whereas 
cytoplasm of infiltrating cells at the non-regenerated bone defect displays pale 
red stain.  
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2.5 Real time PCR 
 
Total RNA was isolated from the healing rat tibial area with Trizol (Life 
Technologies, Carlsbad, CA). Gene expression was analyzed by real time PCR 
using an ABI PRISM 7500 system (Applied Biosystems, Grand Island, NY), as 
reported.15,20 Real time PCR was done using SYBR premix ex Taq (Takara, 
Otsu, Japan) and the following rat Sost specific primers: 5´-
GAGTACCCAGAGCCTCCTCA-3´ (sense) and 5´- 
AGCACACCAACTCGGTGA-3´ (antisense). Gene expression of osteocalcin 
(OC) and vascular endothelial growth factor (VEGF) was analyzed using 
TaqManMGB probes obtained by Assay-by-DesignSM (Applied Biosystems). The 
housekeeping gene 18S rRNA was amplified in parallel with tested genes. Fold 
change of gene expression was calculated based on the cycle threshold (Ct) 
value algorithm represented by 2-∆∆Ct, where ∆∆Ct = ∆Cttarget gene - ∆Ct18S as 
described.15 
 
2.6 Statistical Analysis 
 
Results are expressed as mean ± SEM. Statistical evaluation was carried out 
with nonparametric Kruskal-Wallis test and post-hoc Dunn´s test or Mann 
Whitney test, when appropriate. A value of p<0.05 was considered significant. 
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3. Results 
3.1. Changes in bone structure and histology 
Here, we used an experimental rat model showing that a diabetic status, as 
shown in Fig.1, aggravates the bone structure deterioration related to aging 
(Table 1). We evaluated the osteoinductive capacity of each PTHrP peptide 
tested as coated onto a degradable implant to heal a transcortical bone injury in 
this model. Four weeks following implantation of the unloaded foams, 
incomplete repair of the bone defect was observed in aged rats, an effect more 
dramatic in those with DM, as shown by 2D (Fig. 2) and 3D (frontal and sagittal 
views) (Fig. 3) µCT images. Furthermore, in the diabetic aged rats, the 
regenerating tibial defect containing the unloaded material showed structural 
changes including a decrease in cortical BV/TV and cortical thickness but 
increased cortical BS/BV (Fig. 4), as well as decreased trabecular BV/TV and 
an increase in both trabecular BS/BV and trabecular separation (Fig. 5), 
compared to non-diabetic aged controls. In contrast, rats implanted with PTHrP 
(1-37) or PTHrP (107-111)-loaded foams showed complete healing of the defect 
in both groups of rats, as depicted by µCT images (Fig. 2 and 3), accompanied 
by reversal of the aforementioned changes in bone structure parameters (Fig. 4 
and 5).  
Consistent with these results, histological assessment of the regenerating 
bone defect area showed abundant newly formed bone tissue around the 
osteointegrated HA-Gel foam, associated with the implant containing each 
PTHrP peptide, at the time period evaluated (Fig. 6). 
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3.2. Changes in gene expression 
We also assessed the expression of various osteoblastic genes in the tibial 
defect during bone regeneration following 4 weeks of biomaterials implantation 
in both groups of aged rats. Each type of PTHrP-containing foam in these 
animals was found to induce overexpression of osteocalcin (a late osteoblast 
differentiation marker) and VEGF (a key angiogenic factor) in the regenerating 
area (Fig. 7). In addition, the expression of Sost -the gene encoding sclerostin, 
an important inhibitor of the Wnt pathway with a paramount role as a regulator 
of bone turnover21- was increased in the diabetic rats during bone repair; but 
decreased dramatically by the presence of each PTHrP peptide in the implant in 
aged rats independently of the diabetic status (Fig. 7).  
 
 
4. Discussion  
 
In the present study, we evaluated the ability of two PTHrP-derived 
peptides to heal a transcortical defect in rats with two prevalent conditions – 
aging and DM- which are prone to skeletal fractures. We show that both 
peptides tested locally delivered at the injury site were similarly efficient to 
regenerate this noncritical defect in the tibia of old rats independently of their 
diabetic status.  
In humans over 30-35 years of age, bone mineral density and content 
starts to decrease, and with further aging, structural changes in bone, including 
cortical bone volume and trabecular number reduction, trabecular spacing 
increase and cortical bone thinning become manifest.22 Several factors during 
aging have been proposed to promote these changes including an increase of 
reactive oxygen species, bone cell senescence induced by shortage of 
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telomeres or environmental factors that affect cellular DNA.23  DM, being more 
frequent in the elderly,3 is also related to poor bone quality in close relationship 
with the accumulation of advanced glycosylated end-products (AGEs).24 Even 
though types 1 and 2 DM affect bone differently,25 both types have been 
associated to increased fracture risk due to reduced bone formation.26,27  
Impaired bone filling of a noncritical defect created at the femoral mid-
shaft was recently observed in obese adult Zucker rats with insulin resistance.28 
In agreement with these observations, our results show that DM worsens the 
healing of a bone defect generated in the tibial metaphysis of aged rats, as 
shown by histological and gene expression evaluation in the bone injury area. 
Several mechanisms have been proposed to be responsible for these 
observations such as high glucose-induced deleterious actions on osteoblasts 
through glycation and oxidation.24,29  
Current anabolic therapies to prevent osteoporotic fractures prevalent in 
aging subjects are based on intermittent s.c. administration of PTH-derived 
peptides.30,31 More recently, PTH (1-34) has been further evaluated in various 
bone repair animal models.32 The same type of systemic PTH (1-34) 
administration as used to increase bone accrual improved endochondral and 
intramembranous bone regeneration –as occurs after bone fractures and 
cortical bone injury, respectively- by targeting various stages of bone 
regeneration. Daily injection of a high dose of PTH (1-34) (200 µg/Kg) enhanced 
callus formation following a tibial fracture in old rats.33 Of note, a lower (75 
µg/kg) dose of PTH (1–34) per day induced bone regeneration of subcritical 
femoral defect in type 2 diabetic rats, although less efficiently than in non-
diabetic controls.28  In addition, daily s.c. injections of a PTHrP analogue based 
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on its N-terminal 1-34 sequence (RS-66271), at 10 µg/Kg, was effective for 
preventing impaired healing of a noncritical ulnar defect in rabbits treated with 
prednisone.34 Moreover, either the native N-terminal PTH-like fragment of 
PTHrP or the PTH-unrelated PTHrP (107-139) peptide systemically 
administered for two weeks to type 1 diabetic mice accelerated bone 
regeneration following marrow ablation.12,13 We also recently demonstrated the 
osteoinductive properties of PTHrP (107-111) peptide as coated onto different 
ceramic implants (including that used here) to fill bone defects in non-diabetic 
young rats or rabbits.15,16  
Our present results show that local delivery of PTHrP (1-37) or PTHrP 
(107-111) by coating a degradable material as implant in a tibial defect cavity 
induces similar and positive bone regeneration features –affecting both cortical 
and trabecular compartments in the bone injury healing area- in both non-
diabetic and diabetic aged rats. This osteoinductive effect of each PTHrP 
peptide was accompanied by gene overexpression of OC and VEGF, but 
downregulation of Sost gene, in the regenerating tibial area of both groups of 
old rats, consistent with the osteogenic and angiogenic features of PTHrP 
through its N- and C-terminal domains.11 Of particular interest in this context, 
Sost antagonism -which promotes predominantly modeling-based bone 
formation at trabecular and cortical bone surfaces35- has been proven effective 
to promote bone regeneration in rats with type 2 DM.28  
Local delivery of PTHrP peptides at the injured area as used here might 
facilitate reaching their bone cell targets and thus increase their efficacy 
compared to systemic therapy. In fact, consistent with previous in vitro data 
using PTHrP (107-111)-coated on various bioceramics -including the same 
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ceramic foam as the one used here as carrier15-, PTHrP (1-37) was also rapidly 
released from the material into the surrounding medium. Assuming similar 
release kinetics for each PTHrP peptide in our in vivo setting, no significant 
amount of each peptide is likely to remain in the implant after 5 days; supporting 
the current idea that an initial burst of each PTHrP peptide might be sufficient to 
improve bone healing.15,16 PTHrP acts as a pivotal endogenous stimulator of 
bone formation through autocrine, paracrine and even intracrine actions on 
committed osteoblast precursors enhancing their differentiation and reducing 
osteoblast apoptosis.36 For PTHrP to play such predominant role on osteoblast 
differentiation and survival, control mechanisms must exist to ensure that only 
short-lived, high levels of PTHrP are available to local targets, since persistently 
increased local PTHrP levels –as occurs for PTH in hyperparathyroid patients- 
would favor increased osteoclastogenesis.11 Interestingly, in this regard, PTHrP 
haploinsufficiency has been shown to impair healing of a mid-femur fracture in 
mice.37 Our results support the validity of a strategy based on the local delivery 
of the PTHrP peptides tested to promote bone regeneration in the setting of 
DM- and age-related osteopenia. 
 
5. Conclusions 
The present study demonstrates that delivery of either PTHrP (1-37) or 
PTHrP (107-111) from degradable HA-Gel implants to a noncritical tibial defect 
counteracts the adverse effects imposed by age and DM on bone regeneration 
in rats. Our findings suggest the suitability of this strategy to promote bone 
healing in both conditions.  
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Figure legends 
Fig. 1. DM-related parameters (A-C) and body weight (D) in old and diabetic 
rats and in old nondiabetic controls. Experimental details are described in 
Materials and Methods. Results are mean ± SEM (n=10). *p<0.05 vs old (non-
diabetic) controls. 
Fig. 2. Representative 2D images by µCT of the proximal tibial metaphysis 
comprising the defect area with the different HA-Gel implants, containing or not 
PTHrP (1-37) or PTHrP (107-111) at 4 weeks after surgery in old rats with or 
without DM. Images show cortical (solid square) or trabecular (dotted square) 
peri-implant regions where the regions of interest (ROIs) were acquired. Arrows 
denote the areas were the defect was performed.  
Fig. 3. Representative 3D images by µCT of the area surrounding the different 
HA-Gel implants, containing or not PTHrP (1-37) or PTHrP (107-111) at 4 
weeks after surgery in aged rats with or without DM. The upper row shows a 
frontal view of the bone defect, while the lower row depicts a sagittal view of the 
inner cortical bone structure surrounding the defect, clearly indicating that bone 
regeneration is improved in the presence of the PTHrP peptides.  
Fig. 4. Bone cortical parameters in the rat tibial defect holding each type of HA-
Gel implant in old and diabetic rats and in old nondiabetic controls. Results are 
mean ± SEM (n=5). *p<0.05 vs unloaded scaffold in nondiabetic controls; 
ap<0.05 vs unloaded implant in diabetic rats. 
Fig. 5. Bone trabecular parameters in the healing tibial defect containing each 
type of HA-Gel implant in old diabetic rats and in old nondiabetic controls. 
Results are mean ± SEM (n=5). *p<0.05 vs unloaded scaffold in nondiabetic 
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controls; ap<0.05 vs unloaded implant in diabetic rats. 
Fig. 6. Representative light microscopy images of Masson’s stained tissue 
sections corresponding to the area surrounding the different HA-Gel implants at 
4 weeks after implantation into a transcortical defect in the rat tibia of old rats 
with or without DM. BD = Bone defect; NB = Newly formed bone. Arrows show 
the presence of residual HA-Gel material (inset). 
 
Fig. 7. Changes in gene expression (by real time PCR) of bone-related factors 
in the regenerating tibial defect at 4 weeks after implantation of the different 
scaffolds (HA-Gel) with or without each PTHrP peptide in old and diabetic rats 
and in old nondiabetic controls. Results are mean ± SEM (n=5). *p<0.05 vs 
unloaded scaffold in non diabetic controls; ap<0.05 vs unloaded scaffold in 
diabetic rats. 
Supplementary Figure Legends 
Supplementary Fig. 1. Representative digital (A) and scanning electron 
microscope (B) images of HA-Gel foams. 
Table 1.  Histomorphometric analysis at the distal femoral metaphysis of aged 
rats, with or without DM, and younger rats as age control.  
 Young control Old control Old diabetic 
BV/TV (%) 29.71 ± 1.01 24.34 ± 1.44* 17.48 ± 1.89**,# 
Trabecular thickness (µm) 133.45 ± 7.34 146.87 ± 15.08 104.88 ± 9.36*, # 
Trabecular separation (µm) 307.25 ± 8.66 432.69 ± 61.36* 577.15 ± 36.64** 
Trabecular number 2.24 ± 0.09 1.75 ± 0.17* 1.63 ± 0.14* 
   Results are mean ± SEM (n=5). *p<0.05; **0.01 vs the corresponding younger 
group; #p<0.05 vs old nondiabetic control. 
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